1 wipo national workshop on intellectual property for diplomats sanaa, republic of yemen 20-21 march...
TRANSCRIPT
![Page 1: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/1.jpg)
1
WIPO National Workshop onIntellectual Property for Diplomats
Sana’a, Republic of Yemen20-21 March 2007
The TRIPS Agreement
and Public Health
Roger Kampf
WTO Secretariat
![Page 2: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/2.jpg)
2
I.Overview:
Relevant TRIPS ProvisionsTransition Periods
![Page 3: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/3.jpg)
3
TRIPS Provisions ofDirect Relevance to Public Health
• TRIPS Objectives and Principles
• Patents (incl. compulsory licences)
• Exhaustion
• Protection of Undisclosed Information
• Competition
• Measures against Counterfeiting
• Transition periods
![Page 4: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/4.jpg)
4
« Patent Table »
Art.27.1: Patentable Subject-Matter
↓ ← Exclusions: Art.27.2 + 3
Art.29: Patent Application
↓Art.28: Rights conferred ← Exceptions /
Limitations: Art. 30 + 31
↓Art.33: 20 Years of Protection
![Page 5: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/5.jpg)
5
Article 30: Exceptions
• Exceptions may be provided if they– are limited– do not unreasonably conflict with normal
exploitation of the patent and– do not unreasonably prejudice the legitimate
interests of the patent owner, taking account of the legitimate interests of third parties
• Examples in national legislation:– Experimental use– Use to develop test data required to obtain
marketing approval
![Page 6: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/6.jpg)
6
Article 31: Compulsory Licences
• Use of invention without authorization by right holder:– government use– use by third parties
• not limited to specific purposes• must meet certain conditions, including:
– prior efforts to obtain voluntary licence
exception: public non-commercial use or national emergency
– predominantly for supply of domestic market
exception: adjudicated anti-competitive practices– adequate remuneration paid to patent owner
⇒ Doha Declaration / Para.6 System
![Page 7: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/7.jpg)
7
Exhaustion of Rights
• DS mechanism does not apply• Except for: national / MFN
treatment obligations• Effects in pharmaceutical sector
⇒Doha Declaration: freedom to establish regime which best fits domestic policy considerations
![Page 8: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/8.jpg)
8
Article 39.3: Data Exclusivity
• Members are obliged to protect test data against:– unfair commercial use when:
• marketing approval for pharmaceuticals or agro-chemicals requires submission of undisclosed data;
• new chemical entities are utilized;• origination of data involves considerable efforts;• information is not publicly available
– disclosure, unless:• disclosure is necessary to protect the public• steps have been taken to protect the data against
unfair commercial use
![Page 9: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/9.jpg)
9
Transition Periods
1996 2000 2005 2013 2016_________________________________ ↓ ↓ ↓ ↓ ↓
Industrialised DCs and DCs LDCs 1) LDCsCountries Economies products · pharma
in Transition 1) not (patents &
previously test data)
patented · EMRs
waived
1) National treatment and MFN treatment obligations apply as of 1996
![Page 10: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/10.jpg)
10
II.
The Doha Declaration on the TRIPS Agreement and Public Health
![Page 11: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/11.jpg)
11
The Declaration: General Statements
• Recognition of the gravity of the public health problems...,especially those resulting from HIV/AIDS, tuberculosis, malaria and other epidemics
• Recognition that intellectual property protection is important for the development of new medicines and recognize concerns about its effects on prices
• Agreement that the TRIPS Agreement does not and should not prevent Members from taking measures to protect public health.
• Reaffirmation that TRIPS can and should be interpreted and implemented in a manner supportive of Members’ right to protect public health and, in particular, to promote access to medicines for all
![Page 12: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/12.jpg)
12
Content of the Declaration
• Guidance for disputes• Clarification compulsory licences:
– right to grant– freedom to determine the grounds
• Clarification of emergency situations:– right to determine what constitutes a national
emergency of other circumstance of extreme urgency
• Clarification of exhaustion:– freedom to establish own regime
• Transfer of technology:– reaffirmation of Article 66.2 commitment
![Page 13: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/13.jpg)
13
Instructions for Further Work / Implementation
• Find expeditious solution to difficulties of Members with insufficient / no manufacturing capacities in pharmaceutical sector in making effective use of compulsory licensing:⇒ General Council Decision of August 2003 (WT/L/540);
Chairman’s Statement (WT/GC/M/82, para.29)⇒ General Council Decision of 6 December 2005 (WT/L/641) - Protocol Amending the TRIPS Agreement; Chairman’s Statement (WT/GC/M/100)
• Extend LDC transition period as regards protection and enforcement of patent rights / undisclosed information in the field of pharmaceuticals:⇒ TRIPS Council Decision extends LDC transition period until 1/1/2016 (IP/C/25)⇒ General Council Decision waives obligations under Article 70.9 (WT/L/478)
![Page 14: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/14.jpg)
14
III.
August 2003 Decision:
Implementation of Paragraph 6
of the Doha Declaration on the
TRIPS Agreement and Public Health
![Page 15: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/15.jpg)
15
What is the problem ?
• Members can issue compulsory licences for importation / domestic production
• Concerns: – availability of supply from generic producers
in third countries– mandatory patent protection for pharma
products as from 2005 in exporting countries with important generic industry
• Problem: Art. 31(f) requires production under compulsory licenses “predominantly for the supply of the domestic market of the Member“
![Page 16: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/16.jpg)
16
Solution: “Paragraph 6 System” (1)
• August 2003 Decision is about addressing health problem in importing Member and legal problem in exporting Member
• Decision consists of three waivers and calls for TRIPS amendment
• General Council Chairman’s statement
• Decision in effect since 30 August 2003, terminates when amendment replaces it for each Member
![Page 17: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/17.jpg)
17
Three Distinct Waivers
• Of 31(f) to exporting Members subject to conditions on transparency and safeguards:– scope and coverage: diseases and products– importing Members:
• who is eligible• notification requirements• assessment of manufacturing capacities
– notification requirements applying to exporting Members
– safeguards against diversion
• Of 31(h) to importing Members provided paid in exporting Member on same products
• Of 31(f) to any LDC or developing country part of RTA where at least half LDCs
![Page 18: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/18.jpg)
18
WTO Member with manufacturing capacity
Generic Manufacturer
Government / competent authority
Patent ⇒compulsory licence
Difference BetweenTRIPS 1995 and Para.6 System
WTO Member with insufficient manufacturing capacity for pharmaceuticals
Art. 31(h) may be waived to avoid double remuneration special provisions for RTAs with 50% LDCs other Art.31 conditions continue to apply
PARA.6 SYSTEMArt. 31(f) may be waived if:- notifications are made- special marking/labelling of exported products- other conditions are met
TRIPS 1995Art. 31(f): no export of predominant part of production
![Page 19: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/19.jpg)
19
Other Elements
• Facilitation of transfer of technology
• Annual review substitutes review of waiver by the General Council
• Preservation of existing flexibilities:– including under Article 31(f)– non-violation complaints not available
![Page 20: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/20.jpg)
20
Chairman’s Statement
• Represents key shared understandings of Members:– Good faith use of the system– All reasonable measures to prevent
diversion– Information on manufacturing
capacities (“how”)– Expeditious review in TRIPS Council
and good offices of DG or Chair of TRIPS Council
– List of voluntary partial/full opt-out countries
![Page 21: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/21.jpg)
21
IV.
December 2005 Decision:
Protocol Amending
the TRIPS Agreement
![Page 22: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/22.jpg)
22
GC Decision WT/L/641 of6 December 2005
• Basis: para.11 of August 2003 Decision which instructed TRIPS Council to initiate work on amendment by end 2003 with a view to its adoption within 6 months
• Adopts Protocol amending the TRIPS Agreement and submits it to Members for acceptance
• Protocol open for acceptance until 1/12/2007• Takes effect upon acceptance by two thirds of
membership
→Note that Paragraph 6 System as established under August 2003 Decision continues to apply until entry into force of amendment in a Member
![Page 23: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/23.jpg)
23
TRIPS Amendment
• Waivers of August 2003 Decision are transformed into permanent TRIPS amendment
→ “technical exercise”, no changes in substance to Paragraph 6 System
• Inserts in TRIPS Agreement:– new Article 31bis consisting of:
• 3 waiver provisions of August 2003 Decision• non-application of non-violation complaints• preservation of TRIPS flexibilities
– Annex setting out terms for using Paragraph 6 system
– Appendix to Annex dealing with assessment of manufacturing capacities (former annex to August 2003 Decision)
![Page 24: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/24.jpg)
24
Statements by ChairmanRecognition by MC
• Chairman’s Statement:– re-read prior to adoption of GC Decision– updates list of full opt-out countries
• Chairman’s Statement on non-violation complaints: amendment without prejudice to overall question of applicability of NVCs to TRIPS
• Hong Kong MC in December 2005: Ministers welcome work on TRIPS amendment to implement August 2003 Decision
![Page 25: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/25.jpg)
25
V.
Final Remarks
![Page 26: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/26.jpg)
26
Implementing Legislation in Exporting Members
• Based on information shared in the TRIPS Council:– Norway, Canada, India, EC (in effect) – Korea– Switzerland (in process)
• China also adopted implementing legislation in December 2005
![Page 27: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/27.jpg)
27
Use of Paragraph 6 System• Possible reasons for absence of
notifications so far:– generic medicines available outside patent
system– legislative changes in exporting countries
recent or not yet done– meant to address situation where non-
predominant limit proves restrictive– voluntary licences and reduction of prices
offered by patent owners• Remember: system not to be used if
– local production– voluntary licences– no patents in exporting country– exporting country not a WTO Member
![Page 28: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/28.jpg)
28
Concluding Remarks
• TRIPS forms part of the solution next to other important factors: infrastructure, national health systems, procurement regimes, import tariffs, etc.
• Increased recognition of TRIPS flexibilities
→ but: need for each country to take the necessary steps at national level to avail itself of such flexibilities
• TRIPS beyond Doha: new rules ? What role for DSU and FTAs ?
![Page 29: 1 WIPO National Workshop on Intellectual Property for Diplomats Sanaa, Republic of Yemen 20-21 March 2007 The TRIPS Agreement and Public Health Roger Kampf](https://reader035.vdocuments.us/reader035/viewer/2022062511/5515470d550346c77d8b61b9/html5/thumbnails/29.jpg)
29
Some References• Doha Declaration on TRIPS and Public
Health (WT/MIN(01)/DEC/2)• Decision on the implementation of
paragraph 6 of the Doha Declaration on TRIPS and Public Health (WT/L/540 and Corr.1)
• Decision on an amendment to the TRIPS Agreement (Protocol) (WT/L/641)
• Decision on extension of transition period for LDCs with respect to pharmaceutical products (IP/C/25)
• Decision on general extension of transition period for LDCs (IP/C/40)